Search

Erectile dysfunction is associated with diabetes mellitus with an estimated prevalence of 52.5% in the diabetic population. The first-line therapy for erectile dysfunction is phosphodiesterase type 5 inhibitors, but data suggest that diabetic men may be less responsive than non-diabetic men. Thus, other treatments, including intracavernosal injections, intraurethral prostaglandin, vacuum erection devices and penile prosthetic surgery, should be considered in management of diabetic men with erectile dysfunction refractory to phosphodiesterase type 5 inhibitors. Furthermore, combination therapy of phosphodiesterase type 5 inhibitors and other oral treatments such as arginine or l-carnitine may have synergistic effects resulting in better outcomes. In addition, there are novel therapies such as low-intensity shockwave therapy and stem-cell therapy, which may also be effective in targeted treatment modalities. Furthermore, studies suggest that erectile dysfunction can be improved by targeting concurrent comorbidities or metabolic diseases such as depression, hypertension, hypogonadism, and dyslipidaemia. We present an evidence-based narrative review focusing on the management of erectile dysfunction in diabetic men who have not responded to phosphodiesterase type 5 inhibitors.Both clinicians and patients should be aware of the different management options in diabetic patients who have not responded to phosphodiesterase type 5 inhibitors.

Penile prosthesis surgery represents the end-stage treatment for erectile dysfunction. It is conventionally used only in cases of erectile dysfunction refractory to pharmacological treatments or vacuum constriction devices. Contemporary literature suggests that penile prothesis surgery is associated with a high satisfaction rate and a low complication profile. However, it must be appreciated that the complications of surgery can have devastating consequences on a patient's quality of life and satisfaction and include infection, prosthesis malfunction, penile corporal perforation and penile length loss. Several factors - such as appropriate patient selection, methodical preoperative assessment and patient optimization, specific intraoperative protocols and postoperative recommendations - can reduce the risk of surgical complications. This narrative review discusses the diagnosis and management of both intraoperative and postoperative complications of penile prosthesis surgery.

INTRODUCTION AND OBJECTIVE:Penile fracture (PF) is a rare but potentially catastrophic injury due to the risk of erectile dysfunction (ED) and penile curvature in young, sexually active men. The di...

ANTECEDENTES: La mayor parte de las lesiones testiculares se detectan en etapa temprana. En 10 a 20% de los casos pueden ser benignas. La biopsia por congelamiento ha demostrado ser confiable para evaluar lesiones testiculares. El diagnóstico de histología benigna puede evitar orquiectomías radicales innecesarias y sus complicaciones.OBJETIVO: Evaluar la precisión diagnóstica de la biopsia por congelamiento de lesiones testiculares malignas equívocas, las complicaciones a corto y largo plazos asociadas con este procedimiento.MATERIALES Y MÉTODOS: Estudio retrospectivo efectuado de 2005 a 2015 en un centro hospitalario terciario, en pacientes con exploración testicular con biopsia por congelamiento debido a lesiones testiculares malignas equívocas. Se obtuvieron medidas de precisión diagnóstica. Se registraron las complicaciones a corto y largo plazo. El diseño del estudio se realizó siguiendo las recomendaciones STARD (Standards for Reporting of Diagnostic Accuracy, por sus siglas en inglés).RESULTADOS: Se incluyeron 23 pacientes, con una mediana de seguimiento de diez meses (rango intercuartil: 60). El 73.9 y 26.1% de las lesiones fueron benignas y malignas, respectivamente. No se observaron cambios en el diagnóstico entre el reporte de la biopsia por congelamiento y el reporte definitivo de patología. Las medidas de precisión diagnóstica tuvieron un valor de 100%. El grado de concordancia entre la biopsia por congelamiento y el reporte definitivo de malignidad, fue estadísticamente significativo (κ = 1.0, p

To evaluate the role of PET and MRI fused image study inpatients with primary brain tumors previously treated, to determine the presence of radionecrosis vs residual tumor viability.Primary brain tumors were diagnosed by biopse and MR. 18FDG-PET scan and T1 enhanced MRI follow-up studies were performed between 3 and 5 months after treatment. The 18F-FDG uptake was semiquantitavively calculated by a region-of-interest based Tumor hotspot/normal brain tissue index.Fifty-seven patients were studied, 37 had high grade gliomas; 9 had oligoastrocytomas; 5 had Embrionary tumors; I had a meningyoma and I had an oliodendroglial tumor. All MR studies showed tumor enhancement, without determine wether if it was radionecrosis or tumor viability. PET/MR fused study diagnosed 21 negative studies (30%) and 36 positive results (70%). Tumor hotspot/normal brain tissue index correlated well with the visual analysis registered.Visual analysis in the contrast enhanced MR overestimates the tumoral area, without defining a possible diagnosis between tumor viability and radionecrosis. Metabolic activity in the 18F-FDG PET study in the enhanced area, determines the presence of residual tumor viability. Therefore, coregistration can be used to obtain a more specific diagnosis optimizing the cinical use.